| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Laboratoire d’Immunologie des Tumeurs, Université Paris-Sud, Chatenay Malabry, France; and
Laboratoire d’Immunologie Cellulaire, Institut Gustave-Roussy, Villejuif, France
The lymphocyte activation gene-3 (LAG-3) product is a MHC class II ligand that has been used in vivo to stimulate MHC class II+ APCs to increase tumor-specific immune responses. We investigated whether LAG-3 could also play an adjuvant role in vivo for the induction of humoral and CD4 or CD8 cell-mediated immune responses when immunizing mice with a particulate (hepatitis B surface Ag) or soluble (OVA) Ag. In both cases, coadministration of 1 µg of a soluble fusion protein between murine LAG-3 and the Fc fraction of a murine IgG2a mAb (mLAG-3Ig) as a vaccine adjuvant induced or increased CTL responses to the corresponding MHC class I-restricted peptide. In addition, splenocytes of mice vaccinated with either the particulate or soluble Ag plus mLAG-3Ig exhibited a significantly greater proliferative response than did splenocytes of mice immunized with Ag and a control Ig molecule. Similarly, these splenocytes had a greater Th1- but not Th2-type cytokine response. Finally, mice immunized with Ag plus mLAG-3Ig produced higher titers of Abs than mice immunized with Ag and a control Ig molecule. Thus, these data provide evidence of a novel means of improving the immunogenicity of subunit vaccines.
This article has been cited by other articles:
|
|
 |
|
  B. Li, M. VanRoey, F. Triebel, and K. Jooss Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Clin. Cancer Res., June 1, 2008; 14(11): 3545 - 3554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Casati, C. Camisaschi, L. Novellino, A. Mazzocchi, F. Triebel, L. Rivoltini, G. Parmiani, and C. Castelli Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation J. Immunol., March 15, 2008; 180(6): 3782 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brignone, C. Grygar, M. Marcu, K. Schakel, and F. Triebel A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells J. Immunol., September 15, 2007; 179(6): 4202 - 4211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Casati, C. Camisaschi, F. Rini, F. Arienti, L. Rivoltini, F. Triebel, G. Parmiani, and C. Castelli Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity. Cancer Res., April 15, 2006; 66(8): 4450 - 4460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Andreae, S. Buisson, and F. Triebel MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223) Blood, September 15, 2003; 102(6): 2130 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cappello, F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P.-L. Lollini, A. Amici, E. Di Carlo, P. Musiani, M. Giovarelli, et al. LAG-3 Enables DNA Vaccination to Persistently Prevent Mammary Carcinogenesis in HER-2/neu Transgenic BALB/c Mice Cancer Res., May 15, 2003; 63(10): 2518 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Andreae, F. Piras, N. Burdin, and F. Triebel Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223) J. Immunol., April 15, 2002; 168(8): 3874 - 3880. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
